aTIGIT-IL15 Fusion Antibody
Oncology
Pre-clinicalActive
Key Facts
About MediMabBio
MediMabBio is a private, pre-clinical stage biotech pioneering precision immuno-oncology and autoimmune therapies through a rational protein design platform. The company, co-led by founders with deep expertise from Oxford, KAIST, and Samsung, focuses on engineering novel monoclonal antibodies and cytokine-antibody fusion proteins to overcome limitations of current immunotherapies. With a recent Series B funding of KRW 25.6 billion (approx. $18-20M), a growing pipeline, and a collaborative open-innovation business model, MediMabBio is positioning itself as a global player in next-generation biologics. Its research is supported by partnerships with academic institutions and industry players like Celltrion and Charles River.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |